 Viraleze antiviral could be effective against SAS-CoV-2 and RSV. Boston Consulting Group is involved in positioning and marketing this preventativeearly stage infection product. Viraleze has a fast-track to market in Europe based on antiviral activity, not efficacy of preventing COVID-19 infection. Therefore, minimal regulatory needs in Europe. 